toSense’s CoVa Monitoring System clears the FDA


toSense‘s CoVa Monitoring System (CoVa) received 510(k) clearance from the FDA. Said device is a necklace-like sensor for at-home patients with chronic illnesses, such as congestive heart failure (CHF), COPD, hypertension, and renal failure. It can measure bioimpedance and electrocardiogram waveforms, and then calculate thoracic impedance, heart rate, heart rate variability, and respiration rate.

CoVa is designed for use in the home environment by elderly patients, allowing caregivers to monitor and review data remotely. Several gateways, including Android-based tablets and cellular-based systems like Qualcomm’s 2net, forward the data collected to the cloud.

“CoVa will be transformational in delivering home-health monitoring. Clinicians will have remote access to important, actionable data.” said Matt Banet, CTO at toSense. ” he system’s low price point allows universal access to a new, exciting sensor that could be a critical component of the healthcare system.”

CoVa is aimed for patients with fluid-management problems, those taking diuretic medication, patients living with heart failure or end-stage renal disease, recovering from a coronary artery disease-related event, and/or suffering from recurrent dehydration.